Divergence of Evaluation of Orphan Drugs Between Regulators and Payers- Implications For Patient Access In US And EU
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.981
https://www.valueinhealthjournal.com/article/S1098-3015(17)31315-3/fulltext
Title :
Divergence of Evaluation of Orphan Drugs Between Regulators and Payers- Implications For Patient Access In US And EU
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31315-3&doi=10.1016/j.jval.2017.08.981
First page :
A571
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
936